Avanos Medical Q4 net sales $173.3M (-4.6% YoY); 2024 outlook $685-$705M revenue, adj. EPS $1.30-$1.45

AVANOS MEDICAL, INC.

2023-FY EPS reported -$1.32 revenue$673,300,000

Q4 net sales $173.3M (-4.6% YoY); full-year net sales $673.3M (-1.6%) on lower HA sales.
Q4 GAAP diluted EPS $0.24 (vs $0.21); adjusted EPS $0.36 (vs $0.45). Full-year GAAP loss $(0.21) (vs $0.46 EPS); adjusted EPS $1.03 (vs $1.00).
Free cash flow for 2023 was $14.6M, down from $71.6M in 2022; Q4 outflow $3.4M.
Completed sale of respiratory health business (Oct 2) and acquired Diros Technology (July 24) to focus on Pain Management and Digestive Health.
2024 guidance: net sales $685-$705M (organic growth 3%-6%), adj. gross margin 59.5%-60.5%, adj. diluted EPS $1.30-$1.45.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AVANOS MEDICAL, INC. reported fourth quarter and full-year 2023 results: revenue Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the, EPS Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share o.

Period: fourth quarter and full-year 2023
Revenue: Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the
EPS: Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share o
Result: reported results

Exact text from the filing

Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the full-year, net sales from continuing operations decreased 1.6% to $673.3 million. • Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share of $0.21 per share a year ago, and fourth quarter adjusted diluted earnings per share from continuing operations were $0.36 compared to $0.45 in the prior year. 2023 full-year diluted loss per share from continuing operations were $0.21 compared to diluted earnings per share of $0.46 in the prior year, and adjusted diluted earnings per share from continuing operations were $1.03 compared to $1.00 in 2022.

View on SEC.gov

Browse all earnings releases →

AVANOS MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001606498-24-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.